Neuroendocrine tumour+2
RecruitingStudy on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors
Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors
- Disease:Neuroendocrine tumourGastroenteropancreatic neuroendocrine tumour disease+1
- Substances:EverolimusLanreotide+3
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Everolimus
